Matrix metalloproteinases as modulators of inflammation.

By A. Manicone, J. McGuire. Seminars in Cell and Developmental Biology, 2008

600 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

MATRIX METALLOPROTEINASE-13 DEFICIENT MICE ARE RESISTANT TO OSTEOARTHRITIC CARTILAGE EROSION BUT NOT CHONDROCYTE HYPERTROPHY OR OSTEOPHYTE DEVELOPMENT (2009, background): “MMP-13 can activate other MMPs (50) and inhibition of such cascades may modulate inflammation, cytokine, chemokine and growth factor activity (51).”
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment (2010, background): “Conversion of pro-TNF-α into the soluble cytokinetic form requires proteolytic cleavage by ADAM-17, also known as TNF converting enzyme (TACE), or by several MMPs including MMP-1, -2, -3, -9, -12, -14, -15, and -17 (Manicone and McGuire, 2008).”
Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy (2017, background): “MMP proteolysis of endothelial cell junctional proteins also alters barrier permeability, which aids the infiltration of inflammatory cells to otherwise privileged compartments [56].”